Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670541 | 0.84 | MAPKAPK2 (0.57) | MAPKAPK2ADRB1ALDH1A1USP2TSHR | |
| SCHEMBL8250890 | 0.80 | MAPT (0.40) | MAPKAPK2ALDH1A1TSHRHSD17B10KDM4E | |
| SCHEMBL4421492 | 0.79 | ADRB1 (0.62) | ADRB1ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL2378672 | 0.78 | SMN1; SMN2 (0.53) | KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL16528268 | 0.78 | ADRB1 (0.60) | ADRB1ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL6094124 | 0.76 | ALDH1A1 (0.65) | ADRB1ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL232986 | 0.76 | ALDH1A1 (0.65) | ADRB1ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL5235537 | 0.75 | ALDH1A1 (0.59) | MAPKAPK2ADRB1ALDH1A1USP2TSHR | |
| SCHEMBL5453579 | 0.75 | MAPT (0.51) | MAPKAPK2ADRB1ALDH1A1TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL31349246 | 0.74 | ALDH1A1 (0.58) | MAPKAPK2ADRB1ALDH1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-5622950-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME LTD. (GB) | 1997-04-22 | — | — | US | disclosed |
| US-5576319-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME LTD. (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5432177-A | Pyrrolo-pyridine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1995-07-11 | — | — | US | disclosed |
| EP-0623618-A2 | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994020497-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | MAPKAPK2 3945/4885ADRB1 65/4885ALDH1A1 1901/4885 |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | MAPKAPK2 3928/4885ADRB1 890/4885ALDH1A1 1291/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | MAPKAPK2 3991/4885ADRB1 10/4885ALDH1A1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.